Person:
Bai, Shuhua

Profile Picture
Email Address
Birth Date
Biography URL
https://www.husson.edu/directory/shuhua_bai
Term at University
2009-current
Research Projects
Organizational Units
Job Title
Professor of Pharmaceutical Sciences
Last Name
Bai
First Name
Shuhua
Name
Degrees Held
PhD Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center
M.S. Medicinal Chemistry, Shenyang Pharmaceutical University
B.S. Pharmaceutical Engineering, Shenyang Pharmaceutical University

Filters

20241
Reset filters

Settings

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Publication
    INVESTIGATING BLUEBERRY-DERIVED EXOSOMES AS A NOVEL APPROACH IN NEURODEGENERATIVE DISEASE THERAPY
    (2024-04-18) Warner, April; Canham, Spencer; Yang, Tianzhi; Bai, Shuhua
    Blueberries are renowned for their neuroprotective properties, including their ability to mitigate oxidative stress and enhance cognitive function, making them promising candidates for combating neurodegenerative diseases. This study investigates the potential of blueberry-derived exosomes (BBDExo) as a novel nanosized antioxidant system for neurodegenerative disease therapy. BBDExo were isolated from blueberries through sequential centrifugation and analyzed for protein and polyphenol content. Their stability under gastrointestinal conditions and their uptake by brain endothelial bEND.3 cells were assessed, along with their effects on neuronal SH-SY5Y cells, to ascertain their therapeutic potential. The results showed that BBDExo displayed a nanosized, oval-shaped morphology, averaging 82.7±6.4 nm in size. They demonstrated stability in simulated gastrointestinal environments, maintaining their polyphenol content for up to 4 hours. The uptake of BBDExo by bEND.3 cells was dose-dependent, indicating potential for blood-brain barrier transport. Furthermore, BBDExo significantly enhanced the proliferation of SH-SY5Y cells, with a peak increase of 158.8±1.8% at a concentration of 25 µg/mL. Additionally, BBDExo notably reduced the release of the pro-inflammatory cytokine interleukin-8 in stressed SH-SY5Y cells. These findings suggest that BBDExo offer improved stability and enhanced cellular uptake of bioactive compounds, potentially increasing their effectiveness in neurological applications. The ability of BBDExo to interact with targeted brain inflammatory cells and regulate anti-inflammatory responses demonstrates their promise as an innovative nanomedicine for neurodegenerative diseases, potentially leading to improved therapeutic efficacy and disease management.